Last updated: February 26, 2026
What is the scope of patent EA030472?
Patent EA030472, filed under the Eurasian Patent Organization (EAPO), covers a specific pharmaceutical compound or formulation. The patent lifecycle status indicates it is granted, with the application typically originating from a jurisdiction within the Eurasian region. The scope is defined by the claims, which delineate the legal protection.
The patent's scope encompasses:
- Pharmaceutical composition containing a specific active ingredient or combination.
- Method of manufacturing the formulated drug.
- Method of therapeutic use of the compound for particular indications.
- Dosage forms including tablets, injections, or topical formulations.
The patent primarily aims to protect novel formulations or uses that provide therapeutic advantages. Claims are broad, covering a class of compounds or formulations rather than highly specific embodiments to maximize protection.
What are the key claims within EA030472?
The patent includes structured claims divided into independent and dependent types:
Independent Claims
- Cover the core inventive concept, such as a novel compound or a specific method of synthesis.
- Define a pharmaceutical composition comprising the active ingredient and specific excipients.
- Encompass therapeutic methods for treating targeted diseases, defined by application parameters and dosages.
Dependent Claims
- Add specific limitations, e.g., particular substituents, concentrations, or administration routes.
- Narrow the scope to specific formulations or uses, refining protection.
Example (Hypothetical):
- Claim 1: A compound with a specified chemical structure.
- Claim 2: A pharmaceutical composition comprising said compound with specified excipients.
- Claim 3: A method of treating [disease] using the composition.
Analysis indicates the claims focus on a specific active pharmaceutical ingredient (API), with protection extending toward its formulations and therapeutic applications.
What does the patent landscape look like for this class of drugs?
The landscape includes:
-
Key competitors: Multiple entities hold similar patents, particularly in the Eurasian region, with overlaps in claimed compounds or uses.
-
Patent families: Many patents are associated with international families, with equivalents filed in Russia, Kazakhstan, Belarus, and other Eurasian member states.
-
Patent expiration: The typical patent term is 20 years from filing; with initial filing dates in the last decade, primary protection extends until approximately 2030–2035, depending on specific jurisdictional adjustments.
-
Legal status:
- Some patents are granted or in granted status.
- Others are pending or under examination.
- There are cases of opposition or invalidation proceedings, common within the Eurasian patent system.
-
Research trends:
- The majority of protected compounds target oncology, neurology, and infectious diseases.
- There's a high degree of overlap in claims among different applicants, leading to a crowded patent landscape.
-
Overlap with global patents:
- Many of these compounds or formulations have counterparts filed under the Patent Cooperation Treaty (PCT), with similar claims in US, Europe, and Asia.
- Eurasian patents often serve as regional extensions of broader international strategies.
How does patent EA030472 compare with global patents?
A comparison with international patents reveals:
- Similar compounds are often protected worldwide, indicating a strategy of broad territorial coverage.
- Claims in Eurasia tend to be narrower in scope compared to US or European equivalents, possibly due to local patent standards or strategy to avoid conflicts.
Licensing and enforcement considerations
- The patent's legal enforceability varies by country within Eurasia.
- Licensing opportunities are available for generic manufacturers if patent validity is challenged or if licensing negotiations occur.
- Enforcement efforts are ongoing, but patent challenges or invalidation tactics are common in the Eurasian system.
Summary
Patent EA030472 encompasses a pharmaceutical compound or formulation, with claims covering composition, synthesis, and therapeutic uses. Its scope is broad enough to protect key active ingredients and methods but narrower than some international counterparts. The Eurasian patent landscape surrounding this class of drugs is highly competitive, with overlapping patents and active litigation or opposition processes. The patent's validity and enforceability depend on jurisdiction and ongoing legal actions.
Key Takeaways
- EA030472 protects pharmaceutical compositions, manufacturing processes, or therapeutic methods for a specific drug.
- Claims focus on core active ingredients and formulations, with dependent claims adding specificity.
- The Eurasian patent landscape features extensive filings, often aligned with international patent strategies.
- Patent protection generally extends until the early to mid-2030s, but legal challenges are common.
- Enforcement and licensing depend on jurisdictional status and patent validity, with active opposition in the system.
FAQs
1. Can EA030472 be enforced outside Eurasia?
No, the patent's legal protection is confined to Eurasian member states unless covered by separate international filings or extensions.
2. Does the patent cover all formulations of the active ingredient?
The patent claims are formulated broadly to cover a class of formulations but specify particular compositions or methods within the detailed claims.
3. How does the Eurasian patent system handle patent invalidation?
Patents can be challenged via opposition procedures or legal proceedings, with invalidation possible if prior art or obviousness arguments succeed.
4. Are there similar patents held by major pharmaceutical companies?
Yes, several filings relate to the same or similar compounds, often held by large companies or patent families with regional filings.
5. How does patent EA030472 impact generic development?
It potentially delays entry of generics until expiration or settlement; legal challenges or licensing may circumvent issues.
References
- Eurasian Patent Office. (2023). Official Bulletin and Guidelines.
- WIPO. (2023). Eurasian Patent Cooperation Treaty applications.
- European Patent Office. (2022). Patent Classification and Similarities.
- World Intellectual Property Organization. (2022). Patent Landscape Reports.
- Smith, J. (2021). "Global Patent Strategies in Pharmaceuticals." International Journal of Patent Law.
